Clinical remission among severe asthmatics on monoclonal antibody therapy: real-world outcomes at 2 years.

Fyles, Fred, Burton, Rachel, Nuttall, Amy, Joplin, Hannah, Watkins, Laura and Burhan, Hassan (2024) 'Clinical remission among severe asthmatics on monoclonal antibody therapy: real-world outcomes at 2 years.'. ERJ Open Research, Vol 10, Issue 6, e00261-2024.

Preview

Text PMC11647906.pdf - Published Version Available under License Creative Commons Attribution. Download (276kB) | Preview

Abstract

Real-world data suggest clinical remission is a feasible treatment goal of monoclonal antibody therapy. Evidence of ongoing response post-12 months may be used to inform treatment decisions. Further work is needed to standardise criteria for remission. https://bit.ly/4cA6TkG.

Item Type:	Article
Subjects:	QW Microbiology and Immunology > Antigens and Antibodies. Toxins and Antitoxins > QW 575 Antibodies WF Respiratory System > Lungs > WF 600 Lungs
Faculty: Department:	Clinical Sciences & International Health > Clinical Sciences Department
Digital Object Identifer (DOI):	https://doi.org/10.1183/23120541.00261-2024
SWORD Depositor:	JISC Pubrouter
Depositing User:	JISC Pubrouter
Date Deposited:	23 Jan 2025 08:37
Last Modified:	28 Jan 2025 10:42
URI:	https://archive.lstmed.ac.uk/id/eprint/25883

Statistics

View details

Actions (login required)

Edit Item